PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

PF-4708671 Chemical Structure

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

5 Customer Reviews

  • After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

    PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

    (F) EGR-2 and GFI-1 abundance (n = 5).

    Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

  • Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

    Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

    C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

    Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

  • Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

    Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 M2XwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\GTHh7UUN3ME2wMlgzODJ2IN88US=> NGL1PJpUSU6JRWK=
UACC-893 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTVwMUm4PFYh|ryP MmLQV2FPT0WU
A427 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHCTWM2OD13LkeyOVY4KM7:TR?= M1XjdHNCVkeHUh?=
OCUB-M NF:2T4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTZwNk[xNFIh|ryP MoDCV2FPT0WU
SW684 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjpTHNKSzVyPUeuOVIzPjhizszN M2jaNHNCVkeHUh?=
SK-LMS-1 M4CxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXlTWM2OD17LkCxN|AzKM7:TR?= NYn6SGNvW0GQR1XS
CP50-MEL-B MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPve4tyUUN3ME25MlMxPDF7IN88US=> NGfIOI9USU6JRWK=
NCI-H1651 NETTWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\RS4JKSzVyPUGwMlAzPzZizszN NIXJVZFUSU6JRWK=
ABC-1 M{HTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nKWGlEPTB;MUCuNVA{PyEQvF2= M1;rN3NCVkeHUh?=
OE19 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG5TWM2OD1zMD6xO|M{KM7:TR?= NEX0WXBUSU6JRWK=
DSH1 NEXRRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLDcGlKSzVyPUGwMlg5PzlizszN NFraXYtUSU6JRWK=
SW13 NYD2c|lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjuTWM2OD1zMT65N|E6KM7:TR?= M3OwXXNCVkeHUh?=
MDA-MB-453 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPnPZdKSzVyPUGyMlE3ODNizszN NGm4SpVUSU6JRWK=
647-V M2nVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF{LkO1PFIh|ryP NWTKZ5RzW0GQR1XS
NCI-H2342 NY\0O|hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF{LkO5PVUh|ryP M4nndnNCVkeHUh?=
LB2241-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\MdIxKSzVyPUGyMlU4PzlizszN NHHY[YJUSU6JRWK=
UACC-257 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmzbIRGUUN3ME2xN{41PDV|IN88US=> MYDTRW5ITVJ?
NCI-H661 M2DrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uyd2lEPTB;MUOuOlQ1QSEQvF2= MmnjV2FPT0WU
FADU NEDjdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fUfGlEPTB;MUOuOlk6OiEQvF2= NEDaNFJUSU6JRWK=
A2780 M3\sZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq4fnV7UUN3ME2xN{45ODRzIN88US=> Mni3V2FPT0WU
NCI-H1793 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP5TWM2OD1zND60NFg2KM7:TR?= MVLTRW5ITVJ?
TE-8 M3LZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF3LkO0OlUh|ryP MWDTRW5ITVJ?
HGC-27 NWnIT3BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvITWM2OD1zNj6xOlQ1KM7:TR?= Mom1V2FPT0WU
MMAC-SF M4HobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF5LkO3Nlch|ryP NYXpUZBnW0GQR1XS
Calu-6 MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF6LkG1NVMh|ryP M{WzVnNCVkeHUh?=
HUTU-80 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonjTWM2OD1zOD6zPVU6KM7:TR?= MXnTRW5ITVJ?
SAS NH7yUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF6Lk[0OVUh|ryP M1HMenNCVkeHUh?=
IST-MES1 MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjZWmlwUUN3ME2xPE43PTB6IN88US=> MknDV2FPT0WU
C3A NUezXlNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln3TWM2OD1zOD63PVE6KM7:TR?= Mmn5V2FPT0WU
ES3 NWO3[oFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF6LkizOlQh|ryP NYm0dFVuW0GQR1XS
HSC-2 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETMemRKSzVyPUG5MlY2PDFizszN MmKzV2FPT0WU
T47D NHPWSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD1{MD6xOFg2KM7:TR?= Mn\WV2FPT0WU
EW-7 NWTGfnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXizZlZIUUN3ME2yNE45PTh6IN88US=> MWTTRW5ITVJ?
LN-405 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETK[IZKSzVyPUKwMlg6PjVizszN NWfYfI1xW0GQR1XS
U031 NXTVU4tnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJzLkS4NFIh|ryP NXr4PI5WW0GQR1XS
A549 NHu1RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zPWGlEPTB;MkGuPFQ6OSEQvF2= MV7TRW5ITVJ?
RMG-I MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPMTWM2OD1{Mj6yOlY5KM7:TR?= MUHTRW5ITVJ?
BT-474 M3;lSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGz[INEUUN3ME2yNk43PTVzIN88US=> M3GzdHNCVkeHUh?=
NB69 M4rPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WzUWlEPTB;MkOuNVUzKM7:TR?= NX2yNW9rW0GQR1XS
NB7 M3:3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fwNmlEPTB;MkSuNVg5KM7:TR?= NFPscINUSU6JRWK=
HCC1569 NFL1ZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJ2Lk[xNlUh|ryP M1G5W3NCVkeHUh?=
MEL-JUSO NVrnUJBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrIc2o5UUN3ME2yOE43QTB6IN88US=> NGnpOnpUSU6JRWK=
MDA-MB-175-VII MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ3LkK1NVch|ryP NWCx[lNPW0GQR1XS
HCC1419 M1rRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHoPVNPUUN3ME2yOU43ODB|IN88US=> M4rzW3NCVkeHUh?=
Ca9-22 NYL2NldIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XId2lEPTB;MkWuOlQ{OiEQvF2= M3HnbHNCVkeHUh?=
KGN MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHexdmNKSzVyPUK1Mlc2PDdizszN MYnTRW5ITVJ?
LB373-MEL-D M3jzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\uUGlEPTB;Mk[uNVk{QCEQvF2= NVWxe2pWW0GQR1XS
NCI-H1755 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ4Lki4OFEh|ryP NIXrU5pUSU6JRWK=
D-423MG NHj6S3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF62TFJKSzVyPUK3MlA4OTVizszN NEC0R4lUSU6JRWK=
DK-MG M1LSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWwcmR{UUN3ME2yPE44QDR4IN88US=> NITpSXBUSU6JRWK=
NCI-H1623 NFryOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXCOGl2UUN3ME2yPE45OzR{IN88US=> MnPqV2FPT0WU
KU-19-19 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvRTWM2OD1{OD65PVUh|ryP Ml3GV2FPT0WU
C-33-A NFz5e4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ7LkKxPVgh|ryP MWnTRW5ITVJ?
SCC-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLzTWM2OD1|MD6zN|U1KM7:TR?= MUfTRW5ITVJ?
MG-63 NXLa[4JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj6TWM2OD1|MD61PVk1KM7:TR?= MYrTRW5ITVJ?
LNCaP-Clone-FGC NGrxWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXMbHZKSzVyPUOxMlQ6OjFizszN NX6yeWNnW0GQR1XS
CAPAN-1 NWXlS49qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzhelBKSzVyPUOxMlUzQDZizszN Mnn2V2FPT0WU
GI-ME-N MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNzLkWzOVMh|ryP NWjxdJFmW0GQR1XS
RERF-LC-MS NW\kb3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j6[GlEPTB;M{KuOlc1PyEQvF2= MVrTRW5ITVJ?
KLE NF\1SItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHVSFZKSzVyPUOzMlQ{OzRizszN MULTRW5ITVJ?
KNS-81-FD NHzke5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTN|LkWwNFgh|ryP NEm3WYxUSU6JRWK=
DOK NFH0N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTN2Lk[2NVIh|ryP NEPxUlVUSU6JRWK=
ACHN NHe1V4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rMemlEPTB;M{WuNVU5QCEQvF2= NUnadJJiW0GQR1XS
KYSE-520 M2rqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW4TWM2OD1|NT6yN|YyKM7:TR?= MVLTRW5ITVJ?
SBC-5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTN3LkWxNVYh|ryP NXnBNoJlW0GQR1XS
NCI-H28 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[yZYFKSzVyPUO1MlY3QTVizszN MnuxV2FPT0WU
ES7 M1XxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjhOZlKSzVyPUO2MlIzPDlizszN NXjv[ndTW0GQR1XS
A172 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTN4LkSxPFch|ryP NGr1ZW5USU6JRWK=
UM-UC-3 M1zRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTN5Lki3OFYh|ryP NUWwR4ZXW0GQR1XS
LXF-289 M2q5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPpTmVKSzVyPUO4MlAxPDdizszN MVfTRW5ITVJ?
KP-4 MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjIem4{UUN3ME2zPE41PzN7IN88US=> MYnTRW5ITVJ?
TE-1 NUHESVdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nQSGlEPTB;M{muOlU5QSEQvF2= MVrTRW5ITVJ?
G-402 M1:zfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTRyLkC2NUDPxE1? NHzBbZFUSU6JRWK=
786-0 NGHBVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrnb3o{UUN3ME20NE46ODl4IN88US=> MUTTRW5ITVJ?
K5 NYezS2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvYcVhKSzVyPUSxMlM3QDZizszN NIrKb3BUSU6JRWK=
SK-N-DZ NX7PU2JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7aWGtFUUN3ME20NU4{QDJ|IN88US=> MXvTRW5ITVJ?
OVCAR-4 NWfCdFJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFexNmFKSzVyPUSxMlc2PjhizszN MkCxV2FPT0WU
T84 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTR{LkGyOlMh|ryP MYPTRW5ITVJ?
GCIY M2Xz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrRTZN4UUN3ME20N{4xQDB|IN88US=> NInSPG5USU6JRWK=
BB49-HNC NYTnPG9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\sTWM2OD12Mz6zN|Q5KM7:TR?= MXHTRW5ITVJ?
SNU-C2B NX\nVGYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTR|Lk[0N|Yh|ryP NVvvfo9vW0GQR1XS
TE-6 NUj0bY9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDsd2VKSzVyPUSzMlg5QTRizszN NHnZT49USU6JRWK=
23132-87 M3m2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTR2LkK5O|gh|ryP MoXSV2FPT0WU
DMS-53 M{Hybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTR2LkOzPFQh|ryP M3roN3NCVkeHUh?=
ONS-76 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfVNpJKSzVyPUS0Mlc3PjFizszN NYOyfHJNW0GQR1XS
DMS-273 NFHHV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjybJdKSzVyPUS0Mlk1OyEQvF2= M1:we3NCVkeHUh?=
COLO-824 M4PSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTR3Lki3O|Uh|ryP MUTTRW5ITVJ?
DMS-114 NX75O4JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;NPGlEPTB;NEWuPFkzPyEQvF2= MYXTRW5ITVJ?
YKG-1 NXfkNINET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7xNItKSzVyPUS2MlA{PTVizszN M4\mVHNCVkeHUh?=
RH-18 NFzrbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTR4LkO3N|Mh|ryP NW[5OGxXW0GQR1XS
NCI-H1355 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHDenNKSzVyPUS2MlYyQCEQvF2= MnjBV2FPT0WU
NCI-H2170 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjoUYpKSzVyPUS3Mlc2QDRizszN Mlm0V2FPT0WU
OC-314 NHHPZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nDUmlEPTB;NEeuPFQ4QCEQvF2= NH7sNlBUSU6JRWK=
NCI-H2030 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj3eFlKSzVyPUS3Mlg6ODZizszN NX3sbmgxW0GQR1XS
22RV1 NHTmb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jRU2lEPTB;NEeuPVAyPSEQvF2= MoLnV2FPT0WU
G-401 MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXHVGl5UUN3ME20PE41PDF3IN88US=> NFv2SHVUSU6JRWK=
YAPC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR7LkiwO|Mh|ryP NGLlVldUSU6JRWK=
SW1573 NGTNcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC1cnEzUUN3ME21NE4zPDN3IN88US=> MUXTRW5ITVJ?
COLO-792 NIHGfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn3eYVKSzVyPUWwMlYzOzdizszN MYDTRW5ITVJ?
KNS-62 M4eyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTVyLke1NFgh|ryP NWXqO3ZVW0GQR1XS
NB5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;ieHE{UUN3ME21NU41PTB7IN88US=> MXTTRW5ITVJ?
CP66-MEL NFPCUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknWTWM2OD13MT62OFA5KM7:TR?= MWfTRW5ITVJ?
CaR-1 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LBbmlEPTB;NUKuNFYxPiEQvF2= MWHTRW5ITVJ?
CAL-54 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTV{LkGxNFIh|ryP MYTTRW5ITVJ?
8305C MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jHeWlEPTB;NUKuN|E2KM7:TR?= M3z5[HNCVkeHUh?=
Calu-3 NFLrcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnUUGo3UUN3ME21Nk4{PzN|IN88US=> MkPBV2FPT0WU
AU565 M33lSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTV{LkW1NFkh|ryP M3\CR3NCVkeHUh?=
CW-2 M1TDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPoTWM2OD13Mj64OlU1KM7:TR?= NXX4bZlFW0GQR1XS
BEN MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W0fWlEPTB;NUOuO|g3OiEQvF2= MkfxV2FPT0WU
NCI-H1975 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXzTWM2OD13Mz64PVY3KM7:TR?= MYLTRW5ITVJ?
HCT-116 NFe0VXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonoTWM2OD13ND6wN|I4KM7:TR?= Mnz6V2FPT0WU
SH-4 M2fHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X4NmlEPTB;NUSuNVM5KM7:TR?= Mn7BV2FPT0WU
NCI-H1693 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3MZ3BKSzVyPUW0MlIyODNizszN MVvTRW5ITVJ?
BPH-1 M3;adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7adohKSzVyPUW1MlI5QTJizszN MmX5V2FPT0WU
CAMA-1 M3SzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\YTWM2OD13NT64NVE3KM7:TR?= M2XucXNCVkeHUh?=
A388 NYrkd5JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTV4LkC5PFUh|ryP MU\TRW5ITVJ?
C2BBe1 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG0TWM2OD13Nj6yOlM1KM7:TR?= MnrhV2FPT0WU
GAMG NXSyPGR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHLOJJKSzVyPUW2MlU6PTVizszN NEL6SFFUSU6JRWK=
MKN28 NGjFTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XpVmlEPTB;NU[uPFAyOyEQvF2= NFO2W|dUSU6JRWK=
VA-ES-BJ NF\EOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[yTWM2OD13Nj64O|Q2KM7:TR?= Mm\qV2FPT0WU
HuCCT1 M3LLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX6TWM2OD13Nz6wOFkzKM7:TR?= MVHTRW5ITVJ?
BFTC-905 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7aTnZIUUN3ME21O{4zQDl6IN88US=> MoCzV2FPT0WU
LS-123 NYqzfVRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTV5LkW2Olgh|ryP MWfTRW5ITVJ?
LB996-RCC Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LUVWlEPTB;NUiuNFI5PyEQvF2= NVz4eWhqW0GQR1XS
NCI-H1048 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTwVFlpUUN3ME21PE4zOTh6IN88US=> NID5d|VUSU6JRWK=
COR-L105 NVv2TIExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWyNWNKSzVyPUW4Mlc{OzdizszN MnjjV2FPT0WU
OVCAR-8 NGLkelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL5TWM2OD13OT6xO|E3KM7:TR?= NWTxRnpCW0GQR1XS
SK-N-FI MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\aVHZZUUN3ME21PU4{OjB5IN88US=> M4fJUnNCVkeHUh?=
MES-SA Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTV7LkS1NFkh|ryP Mk\KV2FPT0WU
SCC-9 NVTpcIJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PCWWlEPTB;NUmuOFc2OyEQvF2= MUfTRW5ITVJ?
EFO-27 NUHIUWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITaWGRKSzVyPUW5Mlk1OyEQvF2= M{XDTnNCVkeHUh?=
GT3TKB MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXafodKSzVyPU[wMlYxPDhizszN MUTTRW5ITVJ?
HCC38 NXO4XYhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTZzLkSzO|kh|ryP NV\RSJBSW0GQR1XS
MLMA M4nidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LSeGlEPTB;NkGuOlE3OyEQvF2= MoDUV2FPT0WU
D-566MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfXflZrUUN3ME22N{42OjJ2IN88US=> NHrOT5ZUSU6JRWK=
SF295 NWKx[mtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XkOmlEPTB;NkOuOlY2PSEQvF2= MX\TRW5ITVJ?
ES4 M1Oycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXSepd{UUN3ME22OE41PzF7IN88US=> NH3TdphUSU6JRWK=
CAKI-1 NVTTbVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzaTWM2OD14ND61O|IyKM7:TR?= NGXuVpVUSU6JRWK=
OAW-28 NUPxZldCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H0[WlEPTB;NkSuPVY1PyEQvF2= MULTRW5ITVJ?
NCI-H460 NHLWXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:1WGlEPTB;NkWuNFg6PyEQvF2= NXnTSHJYW0GQR1XS
JAR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2wW2RXUUN3ME22OU42PTF4IN88US=> NW\5[2RSW0GQR1XS
SNU-449 M4\wRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjxOYRKSzVyPU[1Mlc3OTZizszN NV;5bnVlW0GQR1XS
D-392MG Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTZ3Lkm0N|Qh|ryP MlHaV2FPT0WU
EW-22 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX0enZxUUN3ME22Ok4{QTVizszN NVq4fIVNW0GQR1XS
GCT MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTZ5LkC0OFMh|ryP MV;TRW5ITVJ?
NOS-1 M2\2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXKTWM2OD14Nz62PFY4KM7:TR?= NHjKXVdUSU6JRWK=
RH-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTZ6LkW1OVkh|ryP MXLTRW5ITVJ?
HuH-7 NWf0bGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTZ7LkGwNFIh|ryP MULTRW5ITVJ?
NUGC-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjTbW5EUUN3ME23NE46PjR2IN88US=> MY\TRW5ITVJ?
IST-SL1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTdzLkKzNlQh|ryP MmLLV2FPT0WU
SHP-77 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorCTWM2OD15Mj6xNVkh|ryP M{HKXXNCVkeHUh?=
SW1116 NEPyeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrMdoxrUUN3ME23Nk4yPDB5IN88US=> NF[4ZW9USU6JRWK=
LK-2 M1fpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\STWM2OD15Mj64OlEzKM7:TR?= NInjeGtUSU6JRWK=
U-2-OS MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\XfoVKSzVyPUezMlE5OjhizszN MXjTRW5ITVJ?
KYSE-150 MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTd|Lk[xNVgh|ryP MnHsV2FPT0WU
U251 NHHZRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHFTWM2OD15Mz64NVY5KM7:TR?= M1zVWnNCVkeHUh?=
HT-1080 NHq3RWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTd2LkK1O|Qh|ryP NHi2O2VUSU6JRWK=
NCI-H1437 NYjH[HdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzDZ4ZKSzVyPUe0MlY{OjZizszN M124e3NCVkeHUh?=
HPAF-II NYXWXpc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vISmlEPTB;N{SuOlQyPSEQvF2= NH:4[W5USU6JRWK=
Becker M17Xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLlUHhKSzVyPUe1MlEyODVizszN MlHSV2FPT0WU
PANC-10-05 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTd3LkK4OlUh|ryP M{GxdHNCVkeHUh?=
TYK-nu NWXFenNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTZTWM2OD15NT6zNVAzKM7:TR?= MVPTRW5ITVJ?
SKG-IIIa MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXlR3Q4UUN3ME23OU4{OzRzIN88US=> NEjCRlFUSU6JRWK=
NCI-H1993 MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLK[YRKSzVyPUe1Mlc{QTdizszN NGr4T|FUSU6JRWK=
S-117 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K5dGlEPTB;N{WuO|U2KM7:TR?= Mn31V2FPT0WU
HuO9 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\yZldKSzVyPUe2MlAxPDhizszN MkHMV2FPT0WU
CAL-51 M{DmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDFTYFKSzVyPUe2MlExODZizszN NI\SeldUSU6JRWK=
BT-20 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrFPXhvUUN3ME23Ok4zOTZ6IN88US=> MnPNV2FPT0WU
LB831-BLC MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL1R3BbUUN3ME23Ok4{OjF5IN88US=> MkH3V2FPT0WU
LB1047-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[we|VCUUN3ME23Ok44PjF7IN88US=> NVnWc5U5W0GQR1XS
ES8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S2[mlEPTB;N{iuNFA4OyEQvF2= NETITHNUSU6JRWK=
UMC-11 M1vIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M332XmlEPTB;N{iuNFg5PCEQvF2= NWXWPFRXW0GQR1XS
NCI-H226 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLLb4dYUUN3ME23PE4yOzF3IN88US=> MUTTRW5ITVJ?
IGROV-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnUNZVYUUN3ME23PE42PTVizszN NGHRemFUSU6JRWK=
BHY MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITPc3ZKSzVyPUe5MlU6PiEQvF2= M3L1c3NCVkeHUh?=
MKN45 NXvzeZhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL5cGxKSzVyPUiwMlMyPzRizszN MVLTRW5ITVJ?
IA-LM MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrHTWM2OD16MD6zOVEyKM7:TR?= M{j6TXNCVkeHUh?=
WM-115 NXzh[|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG3Z3pKUUN3ME24NU41OTF2IN88US=> MlTPV2FPT0WU
VMRC-RCZ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\HTWM2OD16MT60OFI2KM7:TR?= NVr6TIFsW0GQR1XS
NCI-H2291 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRThzLk[4OFIh|ryP NHfzV4dUSU6JRWK=
MCF7 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTh|LkK4PVch|ryP NV:xeWl7W0GQR1XS
639-V M2rUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:yfIpKSzVyPUi0MlYyOjlizszN M1vSOHNCVkeHUh?=
RT4 MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHVTWM2OD16NT6yOFA{KM7:TR?= NUXFUZB3W0GQR1XS
NCI-H2405 M4HROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHvTWM2OD16NT6yPVk4KM7:TR?= M2ni[3NCVkeHUh?=
CAL-33 NVfF[4Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fCRWlEPTB;OEWuOlMyPSEQvF2= NIP6NXlUSU6JRWK=
BT-549 M1P6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jubmlEPTB;OEWuPVM5OiEQvF2= NXLXNWFQW0GQR1XS
HT-1197 M1vJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnQXWZ7UUN3ME24PE4yODd5IN88US=> NX7hPYNLW0GQR1XS
G-361 NVfNbVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn2OWViUUN3ME24PE4yPDd2IN88US=> Mn3OV2FPT0WU
LS-411N M{jTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTh7LkOzPFgh|ryP NGPYRWdUSU6JRWK=
HT-144 NUjh[5l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;CdGlEPTB;OEmuOVk6OiEQvF2= MVHTRW5ITVJ?
DJM-1 M1PjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTh7Lki4OFUh|ryP NFfnbYpUSU6JRWK=
CAL-12T NWDQXnJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rCO2lEPTB;OUCuO|g6PSEQvF2= MY\TRW5ITVJ?
MKN7 M{TOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;FTWM2OD17MT6zOVUyKM7:TR?= M2DwVnNCVkeHUh?=
HuP-T3 NVPRUZVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTl4LkGwNFQh|ryP M2HlWXNCVkeHUh?=
SK-MG-1 NGK5XW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHezWo9KSzVyPUm2MlE{PDhizszN NEG5[GRUSU6JRWK=
NCI-H2347 M1vBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLiUYVKSzVyPUm4MlExPDJizszN NH;lfHVUSU6JRWK=
SW872 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX4dZNuUUN3ME2xNFAvPDV4IN88US=> NGPCcoNUSU6JRWK=
COLO-829 M2G3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P1fGlEPTB;MUCwMlU2OyEQvF2= MYXTRW5ITVJ?
MC-IXC M2n4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFyMD62NVUh|ryP Ml[3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

28626016 30423811
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID